American Heart Journal
Volume 156, Issue 1 , Pages 112-119 , July 2008

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004

  • Heli Ghandehari, BS

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA
    • ,
  • Sachin Kamal-Bahl, PhD

      Affiliations

    • Global Outcomes Research, Merck & Co., Inc., West Point, PA
    • ,
  • Nathan D. Wong, PhD, MPH

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA
    • Corresponding Author InformationReprint requests: Nathan D. Wong, PhD, Heart Disease Prevention Program, C240 Medical Sciences, University of California, Irvine, CA 92697.

Received 18 October 2007 ,Accepted 4 March 2008.

References 

  1. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among U.S. adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2003;107:2185–2189
  2. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70:263–269
  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  5. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294:1773–1781
  6. Rosamond W, Flegal K, Furie K, et al. Heart Disease and Stroke Statistics—2008 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146(Electronic publication 2007 Dec 17)
  7. NHANES 1999-2000 Laboratory/Medical Technologists Procedures Manual.
  8. Kidney Disease Outcomes Quality Initiative . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 2):1–290
  9. Kidney Disease Outcomes Quality Initiative . K/DOQI clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2004;4(Suppl 7):13–53
  10. Mosca L for the Expert Panel / Writing Group. Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol. 2004;24:394–396
  11. Shah BV, Barnwell BG, Bieler GS. SUDAAN USERS’ Manual, release 7.5. Cary, NC: Research Triangle Institute; 1997;
  12. SAS Procedures Guide, version 6.12.. 3rd ed. Cary, NC: SAS Institute; 1995;
  13. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–342
  14. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13:652–663
  15. Alsheikh-Ali AA, Jin JL, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499–1501
  16. Volkova NB, Deedwania PC. Dyslipidemia in the metabolic syndrome. In:  Krentz AJ,  Wong ND editor. Metabolic syndrome and cardiovascular disease. New York: Informa Healthcare; 2007;p. 191–217
  17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor in cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  18. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–316
  19. Kashyap ML. Mechanistic studies of high-density lipoproteins. Am J Cardiol. 1998;82:42U–48U
  20. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835–2838

 Presented in part at the American Heart Association Scientific Sessions, Orlando, FL, November 2007. This study was supported by a contract from Merck & Co., Inc., to the University of California, Irvine.

PII: S0002-8703(08)00165-8

doi: 10.1016/j.ahj.2008.03.005

American Heart Journal
Volume 156, Issue 1 , Pages 112-119 , July 2008

Article Tools

* Image Usage & Resolution